13.12.2019 Biofrontera AG  DE0006046113

DGAP-News: Biofrontera AG: Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.


 

DGAP-News: Biofrontera AG / Key word(s): Personnel
Biofrontera AG: Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.
13.12.2019 / 14:02
The issuer is solely responsible for the content of this announcement.


Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.

Leverkusen, Germany, December 13, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, announced today that Christopher Pearson has accepted the appointment as Chief Commercial Officer of Biofrontera Inc. in Woburn, MA effective January 06, 2020. He will be responsible for the divisions Sales & Marketing and Market Access at Biofrontera's US subsidiary.

Particularly Mr. Pearson's proven strategic sales and marketing expertise in growing North American pharmaceutical companies will contribute significantly to the continuous development of sales in the US - Biofrontera's largest market. He succeeds Chief Operating Officer Randy Wilhoite, who left the company at the end of October.

"We are pleased to welcome Christopher Pearson as CCO at our US-subsidiary," commented Hermann Lübbert, CEO of Biofrontera AG. "Chris is a highly regarded leader in the pharmaceutical industry, with a proven track record of successfully executing on sales strategy and building market share. We're confident that Chris' commercial acumen and operational discipline make him the ideal candidate. We're excited to leverage his experience to help Biofrontera reach the next level."

Mr. Pearson joins from Aldeyra Therapeutics, Inc., where he has worked since 2018. In his position as Vice President Commercial Strategy & Development, he was responsible for developing the corporate and commercial strategy and leading the business development team. Prior to that, Pearson held various marketing and sales positions in the pharmaceutical industry for many years, where he acquired his expertise and know-how in areas such as commercial leadership, mergers & acquisitions and the launch of new products. His longest appointment has been with Shire Plc (now Takeda Pharmaceutical Company Ltd.), where Mr. Pearson spent 19 years, building his career from Professional Sales Representative to Vice President US GI Specialty Disease Area Lead, with responsibility for marketing and a 125-people sales team for gastrointestinal drugs. Mr. Pearson earned an MBA from Xavier University Williams College of Business in Cincinnati, OH and a Bachelor of Science in Biology from University of California at Irvine, CA.

-End-

For enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer


+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44 (0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

 

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi(TM) for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



13.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 935745

 
End of News DGAP News Service

935745  13.12.2019 

fncls.ssp?fn=show_t_gif&application_id=935745&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019e 2020e
Umsatzerlöse1 3,12 3,09 4,14 6,13 12,03 21,11 30,00 0,00
EBITDA1,2 -6,09 -8,81 -9,42 -10,95 -13,05 -17,72 -9,00 0,00
EBITDA-Marge3 -195,19 -285,11 -227,54 -178,63 -108,48 -83,94 -30,00 0,00
EBIT1,4 -6,83 -9,62 -10,23 -11,78 -13,93 -18,48 -9,30 0,00
EBIT-Marge5 -218,91 -311,33 -247,10 -192,17 -115,79 -87,54 -31,00 0,00
Jahresüberschuss1 -8,07 -10,72 -11,20 -10,58 -16,10 -9,58 -5,40 0,00
Netto-Marge6 -258,65 -346,93 -270,53 -172,59 -133,83 -45,38 -18,00 0,00
Cashflow1,7 -7,67 -7,93 -9,72 -10,74 -13,12 -13,43 -15,00 0,00
Ergebnis je Aktie8 -0,47 -0,49 -0.48 -0,36 -0,43 -0,20 -0,18 -0,01
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Warth & Klein Grant Thornton

INVESTOR-INFORMATIONEN
©boersengefluester.de
Biofrontera
WKN Kurs in € Einschätzung Börsenwert in Mio. €
604611 4,735 212,36
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
26,31 0,00 0,000 -5,20
KBV KCV KUV EV/EBITDA
14,90 - 9,92 -11,940
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
0,00 0,00 0,00 28.05.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2019 30.08.2019 19.11.2019 20.04.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,33% -22,31% 2,93% -17,08%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Biofrontera AG  ISIN: DE0006046113 können Sie bei DGAP abrufen

Biotechnologie , 604611 , B8F , XETR:B8F